Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: A phase I and feasibility trial of the Gynecologic Oncology Group

Section of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA.
Gynecologic Oncology (Impact Factor: 3.69). 06/2008; 110(3):329-35. DOI: 10.1016/j.ygyno.2008.05.008
Source: PubMed

ABSTRACT To estimate the maximum tolerated dose (MTD) of paclitaxel poliglumex (PPX) in combination with carboplatin in patients with chemotherapy-naive ovarian, primary peritoneal or fallopian tube cancer, and to assess the feasibility of administering multiple cycles of this regimen.
The first 11 patients were treated in a standard 3 + 3 dose-seeking design, with carboplatin held constant at area under the curve (AUC) of 6 and PPX at 225, 175 or 135 mg/m(2). Pharmacokinetics of PPX and carboplatin were evaluated during this dose-seeking component of the trial. MTD was defined by acute dose-limiting toxicities (DLT) in the first cycle. Twenty additional evaluable patients were treated at the estimated MTD to assess the feasibility of this regimen over >or=4cycles.
PPX at 225 mg/m(2) resulted in DLT in 2/3 patients, and was de-escalated first to 175 mg/m(2) and then to 135 mg/m(2). PPX slowly hydrolyzed to paclitaxel and did not alter the pharmacokinetics of carboplatin. DLT within the first 4-cycles were observed in 3 patients (15%) treated at the MTD: neutropenia > 2weeks (2), febrile neutropenia (1). Nineteen patients (95%) experienced grade 4 neutropenia. Sixteen patients (80%) had at least one episode of grade 3 thrombocytopenia. Three patients (15%) had grade 2 and one had grade 3 peripheral neuropathy. Complete response by CA-125 was 75%.
The recommended dose of PPX of 135 mg/m(2) with carboplatin (AUC = 6) in newly diagnosed ovarian cancer was feasible for multiple cycles, but hematologic toxicity was greater compared with standard carboplatin and 3-hour paclitaxel.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian cancer is the deadliest of all gynecological cancers and the fifth leading cause of death due to cancer in women. This is largely due to late-stage diagnosis, poor prognosis related to advanced-stage disease, and the high recurrence rate associated with development of chemoresistance. Survival statistics have not improved significantly over the last three decades, highlighting the fact that improved therapeutic strategies and early detection require substantial improvements. Here, we review and highlight nanotechnology-based approaches that seek to address this need. The success of Doxil, a PEGylated liposomal nanoencapsulation of doxorubicin, which was approved by the FDA for use on recurrent ovarian cancer, has paved the way for the current wave of nanoparticle formulations in drug discovery and clinical trials. We discuss and summarize new nanoformulations that are currently moving into clinical trials and highlight novel nanotherapeutic strategies that have shown promising results in preclinical in vivo studies. Further, the potential for nanomaterials in diagnostic imaging techniques and the ability to leverage nanotechnology for early detection of ovarian cancer are also discussed.
    Critical reviews in oncogenesis 01/2014; 19(3-4):281-315. DOI:10.1615/CritRevOncog.2014011455
  • [Show abstract] [Hide abstract]
    ABSTRACT: A high molecular weight poly(L-glutamic acid) (PLGA) was synthesized by the polymerization of γ-benzyl-L-glutama-N-carboxy (BLG-NCA) and by subsequent removal of the benzyl groups. The influence of initiator, monomer/initiator molar ratio, monomer concentration, and reaction temperature of BLG-NCA polymerization upon the molecular weight was investigated. High molecular weight PBLG of 389,000 were achieved at an appropriate combination of all variables. The protecting benzyl groups in the PBLG were removed by hydrogenation with palladium hydroxide on activated charcoal as a catalyst to give a high molecular weight PLGA (molecular weight = 378 000), containing pendant primary carboxyl groups.
    Polymer-Plastics Technology and Engineering 07/2012; 51(10):1062-1067. DOI:10.1080/03602559.2012.689055 · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review is aimed at combining the published data on taxanes formulations into a generalized Drug Delivery approach, starting from the physico-chemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxanes development, we propose a classification as (i) "surfactant-based formulations" first generation, (ii) "surfactant-free formulations" second generation and (iii) "modulated pharmacokinetics drug delivery systems" third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic.
    Advanced drug delivery reviews 10/2013; 71. DOI:10.1016/j.addr.2013.10.007 · 12.71 Impact Factor

Full-text (2 Sources)

Available from
Mar 26, 2015

Similar Publications